Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Cocrystal Pharma (Nasdaq: COCP) announced on October 27, 2025 that it received a NIH/NIAID SBIR Phase I award of approximately $500,000 to support development of a novel, oral, broad‑spectrum antiviral candidate for influenza A and B. The funds will be used to characterize lead molecules that inhibit an essential function of the influenza polymerase complex. The award is non‑dilutive and intended to assess scientific, technical and commercial potential; successful Phase I completion may enable application for a larger Phase II award. The research is supported under award number 75N93025C00038. Management highlighted the award as validation of its structure‑based drug discovery platform and part of a strategy to secure additional non‑dilutive capital.
Cocrystal Pharma (Nasdaq: COCP) ha annunciato il 27 ottobre 2025 di aver ricevuto una NIH/NIAID SBIR Phase I award di circa $500,000 per supportare lo sviluppo di un nuovo candidato antivirale orale ad ampio spettro per influenza A e B. I fondi saranno utilizzati per caratterizzare le molecole principali che inibiscono una funzione essenziale del complesso polimerasi dell'influenza. Il premio è non diluitivo e inteso a valutare potenziale scientifico, tecnico e commerciale; il completamento con successo della fase I potrebbe consentire la domanda per un premio più ampio di fase II. La ricerca è supportata con il numero di assegno 75N93025C00038. La direzione ha evidenziato il premio come validazione della sua piattaforma di scoperta di farmaci basata sulla struttura e come parte di una strategia per assicurarsi ulteriori capitali non diluitivi.
Cocrystal Pharma (Nasdaq: COCP) anunció el 27 de octubre de 2025 que recibió una subvención SBIR de NIH/NIAID Fase I de aproximadamente $500,000 para apoyar el desarrollo de un candidato antiviral oral de amplio espectro para la influenza A y B. Los fondos se utilizarán para caracterizar las moléculas líderes que inhiben una función esencial del complejo de polimerasa de la influenza. La subvención es no dilutiva y tiene como objetivo evaluar el potencial científico, técnico y comercial; la finalización exitosa de la Fase I podría permitir la solicitud de una subvención mayor de Fase II. La investigación se apoya bajo el número de subvención 75N93025C00038. La dirección destacó la subvención como validación de su plataforma de descubrimiento de fármacos basada en la estructura y como parte de una estrategia para asegurar capital adicional no dilutivo.
Cocrystal Pharma (나스닥: COCP)은 2025년 10월 27일에 NIH/NIAID SBIR Phase I award 약 $500,000의 지원을 받아 인플루엔자 A 및 B에 대한 새로운 경구용 광범위 항바이러스 후보물질 개발을 지원한다고 발표했다. 자금은 인플루엔자 폴리머레이스 복합체의 필수 기능을 억제하는 리드 분자를 특성화하는 데 사용될 것이다. 이 수상은 비희석(non-dilutive)이며 과학적, 기술적 및 상업적 잠재력을 평가하기 위한 것이며, 1상 Phase I의 성공적 완료는 더 큰 Phase II 상을 신청할 수 있도록 할 수 있다. 연구는 상 수여 번호 75N93025C00038로 지원된다. 경영진은 이 상을 구조 기반 약물 발견 플랫폼의 검증으로 보고 비희석 자본을 확보하기 위한 전략의 일부로 강조했다.
Cocrystal Pharma (Nasdaq: COCP) a annoncé le 27 octobre 2025 avoir reçu une subvention NIH/NIAID SBIR Phase I d'environ $500,000 pour soutenir le développement d'un candidat antiviral oral à large spectre pour l'influenza A et B. Les fonds seront utilisés pour caractériser les molécules porteuses qui inhibent une fonction essentielle du complexe polymérase de l'influenza. La subvention est non dilutive et vise à évaluer le potentiel scientifique, technique et commercial; l'achèvement réussi de la Phase I pourrait permettre de déposer une demande pour une subvention Phase II plus importante. La recherche est soutenue sous le numéro de subvention 75N93025C00038. La direction a souligné la subvention comme une validation de sa plateforme de découverte de médicaments basée sur la structure et comme une partie d'une stratégie pour sécuriser davantage de capital non dilutif.
Cocrystal Pharma (Nasdaq: COCP) gab am 27. Oktober 2025 bekannt, dass es eine NIH/NIAID SBIR Phase I Förderung in Höhe von ca. $500,000 erhalten hat, um die Entwicklung eines neuartigen, oralen, breit wirkenden antiviralen Kandidaten gegen Influenzaviren A und B zu unterstützen. Die Mittel werden verwendet, um Lead-Moleküle zu charakterisieren, die eine wesentliche Funktion des Influenza-Polymerase-Komplexes hemmen. Die Förderung ist nicht dilutiv und zielt darauf ab, wissenschaftliches, technisches und kommerzielles Potenzial zu bewerten; ein erfolgreicher Abschluss der Phase I könnte die Antragstellung für eine größere Phase-II-Förderung ermöglichen. Die Forschung wird unter der Fördernummer 75N93025C00038 unterstützt. Das Management hob die Förderung als Bestätigung seiner strukturbasierenden Wirkstoffentdeckung-Plattform hervor und als Teil einer Strategie, zusätzliches nicht dilutives Kapital zu sichern.
أعلنت شركة Cocrystal Pharma (بورصة ناسداك: COCP) في 27 أكتوبر 2025 أنها تلقّت منحة NIH/NIAID SBIR للمرحلة الأولى بنحو $500,000 لدعم تطوير مرشح مضاد للفيروسات عن طريق الفم وواسع الطيف لـ إنفلونزا A وB. ستُستخدم الأموال لتوصيف الجزيئات الرائدة التي تثبط وظيفة أساسية في مركّب بوليميراز الإنفلونزا. المنحة غير مخفّضة وليست مخفّضاً؛ الهدف تقييم الإمكانات العلمية والتقنية والتجارية؛ قد يسمح الإنهاء الناجح للمرحلة الأولى بالتقدم بطلب للحصول على منحة أكبر من المرحلة الثانية. يتم دعم البحث تحت رقم المنحة 75N93025C00038. أشارت الإدارة إلى المنحة كإثبات لمنصة اكتشاف الأدوية المعتمدة على الهيكلة وباعتبارها جزءاً من استراتيجية تأمين رأس مال غير مخفّض إضافي.
Cocrystal Pharma（纳斯达克股票代码：COCP）于 2025年10月27日 宣布，已获得一项 NIH/NIAID SBIR 第一阶段资助，金额约为 $500,000，用于支持开发一种新颖的、口服的广谱抗病毒候选药物，针对 甲型和乙型流感。资金将用于表征抑制流感聚合酶复合体关键功能的先导分子。该资助为非稀释性质，旨在评估科学、技术和商业潜力；成功完成第一阶段可能使申请更大规模的第二阶段资助成为可能。研究在资助编号 75N93025C00038 下获得支持。管理层将该资助视为其基于结构的药物发现平台的验证，以及作为获取额外非稀释资本策略的一部分。
- Approximately $500,000 in non‑dilutive NIH SBIR Phase I funding
- Funding supports characterization of oral influenza A/B antiviral leads
- Award may enable application for larger Phase II funding
- NIH/NIAID recognition validates structure‑based drug discovery platform
- Phase I funding is modest (~$500,000), program remains early‑stage
Insights
Cocrystal secured non-dilutive NIH SBIR Phase I funding of
Cocrystal Pharma$500,000 Phase I award to characterize lead molecules that inhibit an essential influenza polymerase function. The award funds preclinical discovery work and validates the company’s structure-based drug discovery platform without issuing equity.
The program’s near-term progress depends on meeting Phase I milestones and demonstrating scientific and commercial potential to qualify for a larger Phase II award. The award is explicitly for early-stage assessment and does not guarantee further funding or clinical entry; successful Phase I completion is the required trigger for Phase II consideration.
Watch for completion of the Phase I milestones, any Phase II application or award, and announcements about characterized lead molecules or preclinical pharmacology. The award reference is 75N93025C00038 and the date of this announcement is
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This approximately
“This award provides non-dilutive funding to advance our influenza A/B program targeting potent, broad-spectrum drugs toward the path of clinical development,” said Sam Lee, PhD, Cocrystal President and co-CEO. “We appreciate the funding and confidence from NIH, which further validates our structure-based drug discovery platform technology in developing new antiviral treatments.”
The NIH/NIAID Phase I award is designed to assess the scientific, technical and commercial potential of early-stage programs. Successful completion of Phase I may qualify the recipient eligible to apply for a larger Phase II award, which provides additional substantial funding to continue development.
“We have prioritized the pursuit of government and military funding to advance our antiviral pipeline while building shareholder value,” said James Martin, Cocrystal CFO and co-CEO. “This is an important milestone as we continue our work to secure additional non-dilutive capital.”
The research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number 75N93025C00038. The content of this news release is solely the responsibility of Cocrystal and does not necessarily represent the official views of the NIH.
About Influenza
Influenza is a major global health threat that may become more challenging to treat due to the emergence of highly pathogenic avian influenza viruses and resistance to approved influenza antivirals. Each year, there are approximately 1 billion cases of seasonal influenza worldwide, 3-5 million severe illnesses and up to 650,000 deaths. On average, about
Cocrystal Pharma’s Structure-Based Drug Discovery Platform Technology
Cocrystal’s proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral agents. The Company’s platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide Structure Activity Relationships. This helps identify novel binding sites and enables a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of novel broad-spectrum antivirals for the treatment of acute, chronic and potentially pandemic viral diseases.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of Cocrystal’s influenza A/B development program. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, the risks and uncertainties arising from the U.S. government shutdown in October 2025 which may delay or prevent us from receiving funds described in this press release, potential manufacturing and research delays arising from raw materials and labor shortages and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials and test animals as well as similar problems with our vendors and our current and any future contract research organizations (CROs) and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed with, clinical studies, and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of the studies we undertake including any adverse findings or delays, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, development of effective treatments and/or vaccines by competitors, including as part of the programs financed by governmental authorities and potential mutations in a virus we are targeting which may result in variants that are resistant to a product candidate we develop and our liquidity needs. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
What did Cocrystal Pharma (COCP) announce on October 27, 2025?
How will the NIH SBIR Phase I award for COCP be used?
Does the COCP SBIR award dilute shareholders?
What is the NIH award number for Cocrystal's SBIR Phase I grant?
Could COCP receive more NIH funding after this SBIR Phase I award?
What is the investor significance of COCP's SBIR award?
